Jazz Pharmaceuticals (JAZZ) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viatris (VTRS) has outperformed Jazz Pharmaceuticals (JAZZ) over the past year, gaining 74.9% versus a gain of 61.5%. Over five years, JAZZ leads with a +58.1% price change compared with +29.6% for VTRS. Viatris is the larger company by market cap ($19.99 billion vs $14.24 billion), about 1.4 times the size, while Jazz Pharmaceuticals is growing revenue faster (+4.9% vs -3.0%).
On valuation, Viatris trades at a lower forward P/E (6.5x vs 8.5x for Jazz Pharmaceuticals). Viatris pays a dividend yielding 2.76%, while Jazz Pharmaceuticals does not currently pay one. Jazz Pharmaceuticals converts more of its revenue into profit, with a net margin of -8.3% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAZZ | VTRS |
|---|---|---|
| Share price | $219.38 | $17.41 |
| Market cap | $14.24B | $19.99B |
| 1-day change | -1.38% | -0.20% |
| YTD return | +30.85% | +40.08% |
| 1-year return | +61.45% | +74.92% |
| 5-year return | +58.10% | +29.57% |
| P/E ratio (TTM) | 15.04 | — |
| Forward P/E | 8.47 | 6.51 |
| EPS (TTM) | $14.59 | $-0.36 |
| Dividend yield | 0.00% | 2.76% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $4.27B | $14.30B |
| Revenue growth (YoY) | +4.88% | -2.98% |
| Net income (latest FY) | $-356.15M | $-3.51B |
| Gross margin | — | 35.06% |
| Operating margin | -10.08% | -18.62% |
| Net margin | -8.35% | -24.58% |
| 52-week high | $266.38 | $18.43 |
| 52-week low | $128.80 | $9.69 |
| Distance from 52-week high | -17.64% | -5.56% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +34.24% | +13.19% |
| Average volume | 859.22K | 9.25M |
| Shares outstanding | 64.91M | 1.15B |
| Employees | 2,890 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed JAZZ by 13.5 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.76% vs 0.00%).
- Jazz Pharmaceuticals is more profitable, keeping -8.3 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Jazz Pharmaceuticals grew revenue faster in its latest fiscal year (+4.88% vs -2.98%).
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
JAZZ vs VTRS FAQ
Which is bigger, Jazz Pharmaceuticals or Viatris?
Viatris (VTRS) is larger, with a market capitalization of $19.99B compared with $14.24B for Jazz Pharmaceuticals (JAZZ).
Which stock has performed better over the past year, JAZZ or VTRS?
VTRS returned +74.92% over the past 12 months, compared with +61.45% for JAZZ (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Jazz Pharmaceuticals or Viatris?
Viatris pays a dividend yielding 2.76%, while Jazz Pharmaceuticals does not currently pay a regular dividend.
Are Jazz Pharmaceuticals and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.